In vivo and In vitro Studies of Opiates and Cellular Immunity in Narcotic Addicts

  • David M. Novick
  • Miriam Ochshorn
  • Mary Jeanne Kreek
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 288)


Abnormalities of humoral and cellular immunity had been observed in parenteral heroin abusers in studies performed before the epidemic of human immunodeficiency virus (HIV) infection (1,2). In the 1980s, HIV infection, with the resultant development of acquired immune deficiency syndrome (AIDS), became one of the leading causes of morbidity and mortality in parenteral drug abusers (3–5). Due to the long latency period of HIV infection, the number of new cases of AIDS in parenteral drug abusers is expected to increase significantly during the first half of the 1990s. Since HIV infection causes profound impairments of cellular immunity, information on immunologic abnormalities which precede HIV infection in heroin addicts assumes great importance. Such abnormalities could possibly alter the susceptibility of these patients to HIV infection (6) or the rate of progression of HIV infection towards AIDS (7).


Human Immunodeficiency Virus Natural Killer Acquire Immune Deficiency Syndrome Methadone Maintenance Treatment Methadone Maintenance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. J. Kreek, Immunological approaches to clinical issues in drug abuse, Nat.Inst. Drug Abuse Res. Monogr. Ser. 90:77 (1988).Google Scholar
  2. 2.
    M. J. Kreek, Immune function in heroin addicts and former heroin addicts in treatment: pre/post AIDS epidemic, Nat. Inst. Drug Abuse Res. Monogr. Ser. 96:192 (1990).Google Scholar
  3. 3.
    D. M. Novick, I. Khan, and M. J. Kreek, Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection, Bull. Narc. 38:15 (1986).PubMedGoogle Scholar
  4. 4.
    D. C. Des Jarlais, S. R. Friedman, D. M. Novick, J. L. Sotheran, P. Thomas, S. R. Yancovitz, D. Mildvan, J. Weber, M. J. Kreek, R. Maslansky, S. Bartelme, T. Spira, and M. Marmor, HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987, JAMA261:1008 (1989).PubMedCrossRefGoogle Scholar
  5. 5.
    P. A. Selwyn, D. Hartel, W. Wasserman, and E. Drucker, Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program, Am. J. Public Health79:1358 (1989).PubMedCrossRefGoogle Scholar
  6. 6.
    S. A. Marion, M. T. Schechter, M. S. Weaver, W. A. McLeod, W. J. Boyko, B. Willoughby, B. Douglas, K. J. P. Craib, and M. O’Shaughnessy, Evidence that prior immune dysfunction predisposes to human immunodeficiency virus infection in homosexual men, J. AIDS 2:178 (1989).Google Scholar
  7. 7.
    Editorial, Who will get AIDS? Lancet 2:953 (1986).Google Scholar
  8. 8.
    V. P. Dole, M. E. Nyswander, and M. J. Kreek, Narcotic Blockade, Arch. Intern. Med. 118:304 (1966).PubMedCrossRefGoogle Scholar
  9. 9.
    D. M. Novick, E. F. Pascarelli, H. Joseph, E. A. Salsitz, B. L. Richman, D. C. Des Jarlais, M. Anderson, V. P. Dole, and M. E. Nyswander, Methadone maintenance patients in general medical practice: a preliminary report, JAMA 259:3299 (1988).PubMedCrossRefGoogle Scholar
  10. 10.
    D. M. Novick, M. Ochshorn, V. Ghali, T. S. Croxson, W. D. Mercer, N. Chiorazzi, and M. J. Kreek, Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients, J. Pharmacol. Exp. Ther. 250:606 (1989).PubMedGoogle Scholar
  11. 11.
    M. Ochshorn, D. M. Novick, M. J. Kreek, and E. Hahn, High concentrations of naloxone lower natural killer (NK) activity (Abstract), Nat. Inst. Drug Abuse Res. Monogr. Ser. 81:338 (1988).Google Scholar
  12. 12.
    M. Ochshorn, E. Khuri, L. Fahey, J. Craig, R. Rodriguez, M. C. Aldana, H. Albeck, and M. J. Kreek, Normal and abnormal natural killer (NK) activity in methadone maintenance treatment patients (Abstract), Nat. Inst. Drug Abuse Res. Monogr. Ser. 90:369 (1988).Google Scholar
  13. 13.
    M. Ochshorn, D. M. Novick, and M. J. Kreek, In vitro studies of the effect of methadone on natural killer cell activity, Isr. J. Med. Sci. 26:421 (1990).PubMedGoogle Scholar
  14. 14.
    M. J. Kreek, Multiple drug abuse patterns and medical consequences, in: Tsychopharmacology: The Third Generation of Progress, M. Meltzer, ed., Raven Press, New York (1987).Google Scholar
  15. 15.
    J. R. Cooper, Methadone treatment and acquired immunodeficiency syndrome, JAMA 262:1664 (1989).PubMedCrossRefGoogle Scholar
  16. 16.
    D. M. Novick, H. Joseph, T. S. Croxson, E. A. Salsitz, G. Wang, B. L. Richman, L. Poretsky, J. B. Keefe, and E. Whimbey, Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients, Arch. Intern. Med. 150:97 (1990).PubMedCrossRefGoogle Scholar
  17. 17.
    M. J. Kreek, Plasma and urine levels of methadone, N. Y. State J. Med. 73:2773 (1973).PubMedGoogle Scholar
  18. 18.
    M. J. Kreek, Medical complications in methadone patients, Ann. N. Y. Acad. Sd. 311:110 (1978).CrossRefGoogle Scholar
  19. 19.
    V. P. Dole, Implications of methadone maintenance for theories of narcotic addiction, JAMA 260:3025 (1988).PubMedCrossRefGoogle Scholar
  20. 20.
    M. J. Kreek, Using methadone effectively: achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs, Nat. Inst. Drug Abuse Res. Monogr. Ser. (in press).Google Scholar
  21. 21.
    J. R. Cooper, F. Altman, B. S. Brown, and D. Czechowicz, eds., Research on the Treatment of Narcotic Addiction: State of the Art, Nat. Inst. Drug Abuse Treatment Res. Monogr.. U. S. Government Printing Office, Washington, D. C. (1983).Google Scholar
  22. 22.
    V. P. Dole and H. Joseph, Long-term outcome of patients treated with methadone maintenance, Ann. N. Y. Acad. Sci. 311:181 (1978).PubMedCrossRefGoogle Scholar
  23. 23.
    M. Helpern and Y. M. Rho, Deaths from narcotics in New York City, N. Y. State J. Med. 66:2391 (1966).PubMedGoogle Scholar
  24. 24.
    S. A. Geller and B. Stimmel, Diagnostic confusion from lymphatic lesions in heroin addicts, Ann. Intern. Med. 78:703 (1973).PubMedGoogle Scholar
  25. 25.
    M. J. Kreek, L. Dodes, S. Kane, J. Knobler, and R. Martin, Long-term methadone maintenance therapy: effects on liver function, Ann. Intern. Med. 77:598 (1972).PubMedGoogle Scholar
  26. 26.
    P. Cushman and M. H. Grieco, Hyperimmunoglobulinemia associated with narcotic addiction: effects of methadone maintenance treatment, Am. J. Med. 54:320 (1973).PubMedCrossRefGoogle Scholar
  27. 27.
    P. Cushman, Hyperimmunoglobulinemia in heroin addiction: some epidemiologic observations, including some possible effects of route of administration and multiple drug abuse, Am. J. Epidemiol. 99:218 (1974).PubMedGoogle Scholar
  28. 28.
    P. Cushman and C. Sherman, Biologic false-positive reactions in serologic tests for syphilis in narcotic addiction, Am. J. Clin. Pathol. 61:346 (1974).PubMedGoogle Scholar
  29. 29.
    H. Spiera, I. Oreskes, and B. Stimmel, Rheumatoid factor activity in heroin addicts on methadone maintenance, Ann. Rheum. Dis. 33:153 (1974).PubMedCrossRefGoogle Scholar
  30. 30.
    D. M. Novick, Major medical problems and detoxification treatment of parenteral drug-abusing alcoholics, Adv. Alcohol Subst. Abuse 3:87 (1984).PubMedCrossRefGoogle Scholar
  31. 31.
    S. M. Brown, B. Stimmel, R. N. Taub, S. Kochwa, and R. E. Rosenfeld, Immunologic dysfunction in heroin addicts, Arch. Intern. Med. 134:1001 (1974).PubMedCrossRefGoogle Scholar
  32. 32.
    M. J. Kreek, Medical safety and side effects of methadone in tolerant individuals, JAMA 223:665 (1973).PubMedCrossRefGoogle Scholar
  33. 33.
    R. J. Mcdonough, J. J. Madden, A. Falek, D. A. Shafer, M. Pline, D. Gordon, P. Bokos, J. C. Kuehnle, and J. Mendelson, Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptors on T lymphocytes, J. Immunol. 125:2539 (1980).PubMedGoogle Scholar
  34. 34.
    P. Cushman, S. Gupta, and M. H. Grieco, Immunological studies in methadone maintenance patients, Int. J. Addict. 12:241 (1977).PubMedGoogle Scholar
  35. 35.
    R. B. Herberman and J. R. Ortaldo, Natural killer cells: their role in defenses against disease, Science 214:24 (1981).PubMedCrossRefGoogle Scholar
  36. 36.
    J. Ritz, The role of natural killer cells in immune surveillance, N. Engl. J. Med. 320:1748 (1989).PubMedCrossRefGoogle Scholar
  37. 37.
    B. G. Brenner, A. Dascal, R. G. Margolese, and M. A. Wainberg, Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases, J. Leukocyte Biol. 46:75 (1989).PubMedGoogle Scholar
  38. 38.
    G. Rappocciolo, J. F. Toso, D. J. Torpey, P. Gupta, and C. R. Rinaldo, Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus, J. Clin. Microbiol. 27:41 (1989).PubMedGoogle Scholar
  39. 39.
    C. Lopez, P. A. Fitzgerald, and F. P. Siegal, Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections, J. Infect. Pis. 148:962 (1983).CrossRefGoogle Scholar
  40. 40.
    P. M. Novick, P. J. C. Brown, A. S. F. Lok, J. C. Lloyd, and H. C. Thomas, Influence of sexual preference and chronic hepatitis B virus infection on T lymphocyte subsets, natural killer activity, and suppressor cell activity, J. Hepatol. 3:363 (1986).PubMedCrossRefGoogle Scholar
  41. 41.
    M. M. Reddy, A. Englard, P. Brown, E. Buimovici-Klein, and M. H. Grieco, Lymphoproliferative responses to human immunodeficiency virus in asymptomatic drug abusers and in patients with lymphadenopathy or AIPS, J. Infect. Pis. 156:374 (1987).CrossRefGoogle Scholar
  42. 42.
    P. PePaoli, M. Reitano, S. Battistin, P. Martelli, P. Villalata, F. Bergamo, U. Tirelli, A. Carbone, S. Piodato, R. Bosio, and G. Santini, Immunological abnormalities in intravenous drug abusers and relationship to the prolonged generalized lymphadenopathy syndrome in Italy, Clin. Exp. Immunol. 64:451 (1986).Google Scholar
  43. 43.
    G. Poli, M. Introna, F. Zanaboni, G. Peri, M. Carbonari, F. Aiuti, A. Lazzarin, M. Moroni, and A. Mantovani, Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome, Clin. Exp. Immunol. 62:128 (1985).PubMedGoogle Scholar
  44. 44.
    M. P. N. Nair, T. J. Laing, and S. A. Schwartz, Pecreased natural and antibody-dependent cellular cytotoxic activities in intravenous drug abusers, Clin. Immunol. Immunopathol. 38:68 (1986).CrossRefGoogle Scholar
  45. 45.
    N. Kay, J. Allen, and J. E. Morley, Endorphins stimulate normal peripheral blood lymphocyte natural killer activity, Life Sci. 35:53 (1984).PubMedCrossRefGoogle Scholar
  46. 46.
    R. N. Mandler, W. E. Biddison, R. Mandler, and S. A. Serrate, Beta-endorphin augments the cytolytic activity and interferon production of natural killer cells, J. Immunol 136:934 (1986).PubMedGoogle Scholar
  47. 47.
    P. M. Mathews, C. J. Froelich, W. L. Sibbitt, and A. D. Bankhurst, Enhancement of natural cytotoxicity by beta-endorphin, J. Immunol. 130: 1658 (1983).PubMedGoogle Scholar
  48. 48.
    R. E. Faith, H. J. Liang, A. J. Murgo, and N. P. Plotnikoff, Neuroimmuno-modulation with enkephalins: enhancement of human natural killer (NK) cell activity in vitro ,Clin. Immunol. Immunopathol. 31:412 (1984).PubMedCrossRefGoogle Scholar
  49. 49.
    J. Wybran, Enkephalins and endorphins as modifiers of the immune system: present and future, Fed. Proc. 44:92 (1985).PubMedGoogle Scholar
  50. 50.
    N. E. S. Sibinga and A. Goldstein, Opioid peptides and opioid receptors in cells of the immune system, Ann. Rev. Immunol. 6:219 (1988).CrossRefGoogle Scholar
  51. 51.
    E. Hazum, K-J Chang, and P. Cuatrecasas, Specific nonopiate receptors for beta-endorphin, Science 205:1033 (1979).PubMedCrossRefGoogle Scholar
  52. 52.
    M. J. Kreek, Metabolic interactions between opiates and alcohol, Ann. N. Y. Acad. Sci. 362:36 (1981).PubMedCrossRefGoogle Scholar
  53. 53.
    J. E. Blalock, K. L. Bost, and E. M. Smith, Neuroendocrine peptide hormones and their receptors in the immune system, J. Neuroimmunol. 10:31 (1985).PubMedCrossRefGoogle Scholar
  54. 54.
    E. M. Smith and J. E. Blalock, A molecular basis for the interactions between the immune and neuroendocrine systems, Int J. Neuroscience 38:455 (1988).CrossRefGoogle Scholar
  55. 55.
    D. M. Novick, R. W. Enlow, A. M. Gelb, R. J. Stenger, M. Fotino, J. W. Winter, S. R. Yancovitz, M. D. Schoenberg, and M. J. Kreek, Hepatic cirrhosis in young adults: association with adolescent onset of alcohol and parenteral heroin abuse, Gut 26:8 (1985).PubMedCrossRefGoogle Scholar
  56. 56.
    D. M. Novick, R. J. Stenger, A. M. Gelb, J. Most, S. R. Yancovitz, and M. J. Kreek, Chronic liver disease in abusers of alcohol and parenteral drugs: a report of 204 consecutive biopsy-proven cases, Alcoholism: Clin. Exp. Res. 10:500 (1986).CrossRefGoogle Scholar
  57. 57.
    M. J. Kreek, S. L. Wardlaw, N. Hartman, J. Raghunath, J. Friedman, B. Schneider, and A. G. Frantz, Circadian rhythms and levels of beta-endorphin, ACTH, and Cortisol during chronic methadone maintenance treatment in humans, Life Sci. 33 (suppl. 1):409 (1983).PubMedCrossRefGoogle Scholar
  58. 58.
    M. J. Kreek, J. Raghunath, S. Plevy, D. Hamer, B. Schneider, and N. Hartman, ACTH, Cortisol, and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans, Neuropeptides 5:277 (1984).PubMedCrossRefGoogle Scholar
  59. 59.
    S. Zolla-Pazner, D. C. Des Jarlais, S. R. Friedman, T. J. Spira, M. Marmor, R. Holtzman, D. Mildvan, S. Yancovitz, U. Mathur-Wagh, J. Garber, W. El-Sadr, H. Cohen, D. Smith, V. S. Kalyanaraman, J. E. Kaplan, and D. B. Fishbein, Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: Implications for immunologic classification of the disease, Proc. Natl. Acad. Sci. USA 84:5404 (1987).PubMedCrossRefGoogle Scholar
  60. 60.
    R. M. Donahoe, C. Bueso-Ramos, F. Donahoe, J. J. Madden, A. Falek, J. K. A. Nicholson, and P. Bokos, Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers, Ann. N. Y. Acad. Sci. 496:711 (1987).PubMedCrossRefGoogle Scholar
  61. 61.
    P. K. Peterson, G. Gekker, C. Brummitt, P. Pentel, M. Bullock, M. Simpson, J. Hitt, and B. Sharp, Suppression of human peripheral blood mononuclear cell function by methadone and morphine, J. Infect. Dis. 159:480 (1989).PubMedCrossRefGoogle Scholar
  62. 62.
    M. J. Kreek, D. L. Hachey, and P. D. Klein, Stereoselective disposition of methadone in man, Life Sci. 24:925 (1979).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • David M. Novick
    • 1
    • 2
  • Miriam Ochshorn
    • 1
    • 2
  • Mary Jeanne Kreek
    • 1
    • 2
  1. 1.The Rockefeller UniversityNew YorkUSA
  2. 2.Division of GastroenterologyBeth Israel Medical CenterNew YorkUSA

Personalised recommendations